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a b s t r a c t
Background: Invasive lobular cancer (ILC) is biologically distinct from invasive ductal cancer
and there is disagreement regarding appropriate local management of this disease.
Aim: The current study reports long term results comparing mastectomy with breast-
conserving surgery (BCS) in the treatment of ILC.
Material and methods: Study includes 235 women with ILC treated between 1983 and 1987.
All of them underwent axillary dissection and either mastectomy (n=163) or BCS (n=72).
50Gy adjuvant radiotherapy (RT) was given for 53 BCS and 81 mastectomy patients. The BCS
group was compared with the mastectomy group.
Results: Patients treated with mastectomy or BCS had a similar outcome at 15 years with
regard to distant metastasis-free (62% vs. 70%; p, 0.2017) and breast cancer-speciﬁc (62% vs.
70%; p, 0.1728) survival. In the BCS group the actuarial rate of ipsilateral in breast recurrences
was 10% with and 53% without RT at 15 years (relative risk [RR], 0.10; p<0.0001). In the
mastectomygroup theactuarial rate of chestwall recurrenceswas 16%withand13%without
RT at 15 years (RR, 1.45; p, 0.3965). Isolated ipsilateral in breast recurrence did not (RR, 1.73;
p, 0.2767) but isolated chest-wall recurrence did (RR, 2.65; p, 0.0089) adversely affect cause-speciﬁc survival.
Conclusion: Breast cancer speciﬁc survival is not affected by the type of surgical treatment.
BCS and RT is a safe option to control local disease in patients with ILC.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.. Backgroundesults of several studies indicate that breast-conserving
urgery (BCS) followed by radiation therapy (RT) is a suitable
lternative to mastectomy for the management of early-
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oi:10.1016/j.rpor.2011.06.005stage invasive lobular cancer (ILC). Most of these studies
report 5–7-year1–11 and only few of them report 10-year12–15
results. Therefore, the outcome of patients after more than
10 years of treatment has not been well described, and
some doubts have been expressed about the choice of
treatment.. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Table 1 – Baseline characteristics of the two surgical groups.
Characteristic Mastectomy (N=163) BCS (N=72) p-Value
Mean age (years) 58 58 0.9652
Mean tumor size (mm) 21 17 0.0112
Median no. of nodes 12 13 0.4046
Characteristic MastectomyNo. of pts (%) BCSNo. of pts (%) p-Value
Menopause 0.2127
Pre- 54 (33) 18 (25)
Post- 109 (67) 54 (75)
Pathologic T 0.0110
T1 99 (61) 56 (78)
T2 64 (39) 16 (22)
Pathologic N 0.3228
N0 86 (53) 43 (60)
N1 77 (47) 29 (40)
Estrogen receptor 0.0112
Negative 36 (22) 6 (8)
Positive 127 (78) 66 (92)
Hormonal therapy for N1a 0.1040
No 48 (62) 13 (45)
Yes 29 (38) 16 (55)
Chemotherapy for N1b 0.6665
No 58 (75) 23 (79)
Yes 19 (25) 6 (21)
Local irradiation 0.0006
No 82 (50) 19 (26)
Yes 81 (50) 53 (74)
Regional irradiation 0.3051
No 82 (50) 31 (43)
Yes 81 (50) 41 (57)
BCS, breast-conserving surgery.
rouraa 20mg Tamoxifen daily for 3 years for node positive pts (patients).
b 6 cycles of standard CMF (cyclophosphamide, methotrexate, 5-ﬂuo
2. Aim
This report presents the 15-year treatment results of 235
consecutively treated patients with ILC subjected to either
mastectomy or BCS.
3. Material and methods
Two hundred and thirty-ﬁve consecutive treated women with
unilateral Stage I or II invasive lobular breast carcinoma
were treated with axillary dissection and either mastectomy
(n=163) or BCS (n=72) at the National Institute of Oncology,
Budapest between January 1983 andDecember 1987.Operative
decisions regarding breast conservation or mastectomy were
based on patient request, but in the eighties mastectomy was
often recommendedas the surgical treatment of choice. In BCS
patients, routine attempts were made to obtain clear surgical
margins. Surgery consisted of total resection of the primary
tumor with a 1 cm rim of normal tissue. Resection edges were
subjected to frozen section and, when the margin was posi-
tive wider excision was done. At ﬁnal pathologic examination,
8 patients had a positive margin. Five of them underwent re-
excision and in 3 cases conversion to mastectomy was done.
Pathological classiﬁcation (microscopic tumor size, pT andpN)
was done according to the UICC-AJCC TNM System.cil) for node positive patients.
Details of adjuvant treatment policy and technique have
been described previously.16 The clinical-pathological and
treatment characteristics of the patient population are sum-
marized in Table 1. Mastectomy patients had generally larger
primary. Twenty-twopercent of themastectomyandeight per-
cent of the BCS patients had ER negative tumor. The median
RT dose of conserved breast, chest wall or supraclavicular
fossa/apex of axilla was 50Gy (ranges, 44–54Gy, 42–50Gy and
44–52Gy, respectively).
Patients were seen in follow-up at 3- to 6-month intervals
until the end of the 5th year, and annually thereafter. Chest
X-rays, mammograms, bone scans, abdominal ultrasound
examinations and blood tests were performed at least yearly.
The local-regional recurrences were scored on all patients,
including those who also relapsed at distant sites. Malig-
nancy of local-regional recurrence and new primary tumor
was proved by histologic or cytologic examination in every
case. Distant metastases were deﬁned as a recurrence out-
side the target volume. Thus, a supraclavicular recurrencewas
recorded as a regional – not distant – treatment failure. The
median follow-up time for surviving patients was 181 months
(range, 151–210 months).
Survival times were calculated as the time from surgery
to the date of the event or the end of the follow-up period.
Patients lost to follow-up were inserted in the analysis as cen-
sored data. The following end points were studied: any death
for overall survival; death frombreast cancer for breast cancer-
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Table 2 – Survival outcomes by surgical treatment groups.
Mastectomy (N=163) Breast-conserving surgery (N=72) p-Value RR 95% CI
Percent surviving No. of events Percent surviving No. of events
Local recurrence-free survival 15 14 0.05 2.03 1.07–3.85
5 years 92 84
10 years 89 82
15 years 89 77
Locoregional recurrencea-free survival 22 14 0.0644 0.21 0.03–1.62
5 years 89 84
10 years 85 82
15 years 84 77
Distant metastasis-free survival 60 21 0.2017 0.73 0.44–1.2
5 years 73 80
10 years 66 73
15 years 62 70
Breast cancer-speciﬁc survival 60 21 0.1728 0.71 0.43–1.17
5 years 80 86
10 years 66 73
15 years 62 70
Overall survival 87 28 0.0122 0.58 0.38–0.91
5 years 77 85
10 years 62 72
15 years 49 63































wof reference is the mastectomy group.
a This category includes locoregional recurrence came before system
peciﬁc survival; chest wall or ipsilateral in-breast recurrence
or local recurrence-free survival; local or regional recurrence,
hichever came ﬁrst, for locoregional recurrence-free sur-
ival; distant metastasis for distant disease-free survival. The
ctuarial rate of survival was estimated by the Kaplan–Meier
ethod.17 Differences in survival between study groups were
ompared using the log-rank test. In univariate and multivari-
te analysis the Cox’s regression model was used.18 Relative
isk (RR) and associated conﬁdence intervals (CI) were calcu-
ated from the proportional regression coefﬁcients. Statistical
ifferences in proportions and means were assessed by 2-




hree (1.3%) patients were lost to follow-up between 72 and
20 months. During the follow-up period 114 (48.5%) patients
ied, and 121 of them (51.5%) were still alive. The cause of
eath was breast cancer in 81 (34.5%), intercurrent disease in
0 (12.7%), and other malignancy in 3 (1.3%) cases. The results
f univariate analysis showed that pathological T (T1 vs. T2,
= 0.0001) and pathological N (N0 vs. N1, p<0.0001) were but
enopausal status (pre vs. post, p=0.8706), ER status (nega-
ive vs. positive, p=0.2185) and surgery (mastectomy vs. BCS,
= 0.1728) were not signiﬁcantly related to the length of breast
ancer-speciﬁc survival. In multivariate analysis both patho-
ogical T (RR: 1.6; 95% CI: 1–2.5) and N (RR: 7.2; 95% CI. 4.1–12.8)
emained independent predictor of breast cancer speciﬁc sur-
ival. 15-Year survival with T1 or T2 was 73% and 48%, and
ith N0 or N1 was 88% and 35%.lure.
4.2. Surgical treatment groups
The survival outcomes after 5, 10, and 15 years are shown in
Table 2. The 15-year local recurrence-free survival for mas-
tectomy or BCS patients was 89 and 77%, respectively (RR:
2.03; p=0.05). There were no signiﬁcant differences between
the two groups with regard to locoregional recurrence-free,
distant recurrence-free or breast cancer-speciﬁc survival.
However, a signiﬁcant trend was seen toward a better over-
all survival in the BCS group (p=0.0122). It is to be noted that
the incidence of intercurrent death was 15% in the mastec-
tomy and 12% in the BCS group, and three deaths caused by
other malignancy occurred in the mastectomy group.
4.3. Subgroups by radiotherapy
Table 3 shows the actuarial local recurrence rate after 5, 10
and 15 years in the two surgical groups by radiotherapy. The
15-year local recurrence rate for BCS patients without or with
irradiation was 53% and 10%, respectively (RR: 0.10; p<0.0001).
The median time to local failure for irradiated breasts was
87.5 months (2 of 4 relapses occurred after 10 years), as com-
pared to 38.5months for nonirradiated breasts (p=0.0238). The
15-year chest wall recurrence rate for mastectomy patients
without or with irradiation was 13% and 16%, respectively (RR:
1.45; p=0.3965).
4.4. Survival after isolated local recurrenceThere were 14 isolated in-breast and 15 chest wall recurrence.
The median time to an in-breast recurrence was 47.5
months (mean, 59.9; range, 11–164 months). Thirteen of the
fourteen patients with breast recurrence had invasive lobu-
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Table 3 – Actuarial local recurrencea rate after 5, 10, and 15 years in the surgical treatment groups by radiotherapy.
Site of recurrence Nonirradiated Irradiated p-Value RR 95% CI
Percent No. Percent No
Chest wall 9 of 82 12 of 81 0.3965 1.45 0.61–3.45
5 years 8 13
10 years 13 16
15 years 13 16
Ipsilateral breast 10 of 19 4 of 53 <0.0001 0.10 0.03–0.33
5 years 47 2
10 years 53 3
15 years 53 10
The group of reference is the nonirradiated group; p-Values, RR (relative risk), CI (conﬁdence interval), and No. (number) of recurrences shown
are for the entire duration of the follow-up.
a This category includes all local recurrence.
lar carcinoma as the histologic type of recurrence, and one
had mucinous carcinoma. Breast recurrences were treated
with mastectomy (n=6) or tumor excision (n=8). For ﬁve
patients breast irradiation was given after tumor excision.
Seven patients died of breast cancer (n=6) or intercurrent dis-
ease (n=1), and seven of them are alive with no evidence of
disease. The breast cancer speciﬁc survival at 15 years was
74% without and 53% with ipsilateral breast tumor recurrence
(RR, 1.73; 95% CI, 0.67–4.46; p, 0.2767).
The median time to a chest-wall recurrence was 30.0
months (mean, 36.1; range, 7–97 months). Surgery consisted
of excision in 12 and incisional biopsy in 3 cases (multiple-
diffuse recurrence). 11 patients died of breast cancer and 4 are
alive with no evidence of disease. The breast cancer-speciﬁc
survival at 15 years was 66% without and 22% with local recur-
rence (RR, 2.65; 95% CI, 1.39–5.06; p, 0.0089).
5. Discussion
Nowadays mastectomy and breast conservation are offered
as equally effective treatments for women with early-stage
ILC. However, some doubts have been expressed about the
choice of treatment because of poorer results published ear-
lier and of the insidious nature of this disease.1,19–21 In this
report, we documented our experience with ILC in a group
of 235 women treated with either mastectomy or BCS who
weremonitored for amedian of 181months. The results of our
study indicate that patients treated with mastectomy or BCS
have a similar outcome at 15 years after initial surgery with
regard to distant metastasis-free and breast cancer-speciﬁc
survival. After irradiation, the actuarially estimated 15-year
local recurrence rate in the breast or in the chest wall was 10%
and 16%, respectively. There are at least four studies compar-
ing the mastectomy with BCS for the treatment of ILC.7–9,20
Of these, only Anwar et al.20 found that local recurrence rate
was signiﬁcantly higher in patients treated with tumor exci-
sion and RT. At a median follow-up time of 168 months, the
crude rate of local recurrence for mastectomy or BCS patients
was 13.4% and 34%, respectively. In the other three studies the
crude rate of local recurrence ranged from 2.8% to 5.4% for BCS
and RT, which was similar to the local recurrence rate (3–12%)
for mastectomy, at a median follow-up time of 48–60 months.
There are only three studies inwhich ILC patients treatedwithBCS and RT were followed up for more than 120 months after
surgery.13–15 In these series the crude rate of local recurrence
ranged from 8% to 15%. In our series the crude rate of local
recurrence for irradiated BCS patients was 12%.
19 of our patients were treated with BCS alone and 10 of
them (53%) developed local recurrence. In three other series,
some patients were also not subjected to RT after BCS. In
the study of Sastre-Garau et al.12 the local recurrence rate
was not reported for these patients. In the study of Nemoto
et al.21 the crude rate of local recurrence was 29% (4 of 14)
at 48 months and in Holland et al. study7 this rate was 13%
(2 of 15), at a median follow-up time of 55 months. Informa-
tion regarding local relapse rate after longer follow-up of ILC
patients treated with BCS alone is not available. The NSABP B-
06 randomized trial showed that after lumpectomy alone the
cumulative incidence of breast recurrence was 53% at 10 years
for all nonirradiated patients.22
Our practice was that the patients with microscopically
positive surgical margin undergo re-excision. At the ﬁrst
surgery, 11% of our cases had positive surgical margin, and
after re-excision three of them underwent mastectomy. To
obtain clear surgical margins, re-excision is also recom-
mended by others.23,24 However, in the eighties the margins
were evaluated without ink. The high numbers of in-breast
failure in our nonirradiated patients indicate that tumor
deposits may be left behind by primary surgery. One of the
factors which increased the risk of residual disease after BCS
is the insidious nature of ILC, characterized by small inva-
sive “satellites” which appear in the 1–2 cm of otherwise
uninvolved breast tissue beyond the margin of the principal
tumor.25 This phenomenon also underlines the mandatory
use of RT to control microscopic residual disease and to
achieve appropriate local control. In the study of van den
Broek et al.26 the risk of margin involvement was 29% after
the ﬁrst operation and 17% after re-excision, but there was no
inﬂuence of the positive surgical margins on the risk of local
recurrence after RT.
To our knowledge none of the studies compared the sur-
vival of patients with and without local recurrence in ILC. In
our series, an isolated chest wall recurrence predicted signif-
icantly increased mortality (RR, 2.65; p, 0.0089) but in-breast
recurrence did not (RR, 1.73; p, 0.2767). The prognosis following
in-breast recurrence after BCS is much better than following
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Patients treated with BCS and RT may be at persistent risk
f breast failure even 10 years after initial surgery.20,28,29 In our
atients treated with BCS and RT, 2 of 4 in-breast recurrences
ccurred more than 10 years after treatment.
. Conclusions
he results of this study indicate that patientswith early-stage
LC subjected to mastectomy or BCS have a similar outcome
fter long-term follow-up with regard to distant metastasis-
ree and breast cancer-speciﬁc survival. BCS can provide a low
ocal recurrence rate when RT is administered. The majority
f ipsilateral in breast recurrences are but those of chest-wall
ecurrences are not curable.
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